TorreyPines Therapeutics
Phase 1 clinical trial of treatment for Alzheimer disease initiated
Published in Hospital and Nursing Home Week, September 8th, 2005
In preclinical models, NGX267 has shown properties suggesting potential as a therapy for symptomatic improvement and disease modification in Alzheimer disease.
Neil Kurtz, MD, chief executive officer at TorreyPines Therapeutics, said, "NGX267 is the first of several small molecule compounds we are developing to treat Alzheimer's disease."
The phase 1 clinical trial will be conducted at one center in Arizona and will enroll approximately 55 healthy volunteers. The single dose trial will focus on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week
More Articles from Hospital and Nursing Home Week
- Business & Finance
Florida's HMOs continue to make money, study reports - Eli Lilly and company
Study reveals facts about how osteoporosis therapies affect bone cell activity - Institut fur Pathologie, Berlin
Association between hormone replacement therapy and tumor growth reviewed - LifePoint Hospitals, Inc.
Hospital corporation sets pricing of $200 million of subordinated debentures - United Drugs
Drugstore company partners with CMS to offer Medicare drug coverage education - Universal Hospital Services, Inc.
Medical equipment service company reports second quarter, 6-months results - More from this issue of Hospital and Nursing Home Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
